|
Canada-0-ESTATES 公司名錄
|
公司新聞:
- Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
- Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . .
Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
- Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs. com
Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in adults not taking a statin who have known heart disease or are at
- Statin alternative lowers heart-related deaths - Harvard Health
The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
- NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
- LABEL - accessdata. fda. gov
In the cardiovascular outcomes trial, gout was reported in 3 2% of patients treated with NEXLETOL and 2 2% treated with placebo Advise patients to contact their healthcare provider if symptoms of hyperuricemia occur Assess serum uric acid when clinically indicated
- New CLEAR Outcomes Data on NEXLETOL - ESPR | BioPharmaWatch
In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture
- Antihyperlipidemics – Adenosine Triphosphate-Citrate Lyase . . .
The primary end point was a four-component composite of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization
- Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
“These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction - especially for patients who cannot tolerate statin therapy,” said Sheldon Koenig, President and Chief Executive Officer of Esperion
- Bempedoic Acid for the Prevention of Cardiovascular Disease
Bempedoic acid decreases the incidence of major adverse cardiovascular events, with insignificant increases in liver enzyme and creatine kinase levels, gout, myalgia, and cholelithiasis
|
|